UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8...
-Preliminary human clinical trials are anticipated to begin next month- Vantage Health (the “Company”) (OTCQB:VNTH) today announced the...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF...
As filed with the Securities and Exchange Commission on July 24, 2014 Registration No.&nbs...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Vantage Health, Inc. (OTCQB: VNTH) ("Vantage Health" or the "Company"), announced today an article which was published by Adrienne LaFrance of...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...
SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 8-A FOR REGISTRATION OF...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 &n...
Vantage Health Inc. (OTCQB:VNTH) and its parent company Nanobeak Inc. today announced that they have formed a strategic partnership with...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.